# A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors

> **NCT06598007** · PHASE1,PHASE2 · RECRUITING · sponsor: **Crossignal Therapeutics, Inc.** · enrollment: 78 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** CT3001

## Key facts

- **NCT ID:** NCT06598007
- **Lead sponsor:** Crossignal Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2027-06-20
- **Final completion:** 2027-06-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598007, "A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06598007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*